5-[4-(Benzyloxycarbonylamino-imino-methyl)-phenoxy]-pentanoic acid | 147866-92-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[4-(Benzyloxycarbonylamino-imino-methyl)-phenoxy]-pentanoic acid
• 英文别名: 5-[4-(N-phenylmethoxycarbonylcarbamimidoyl)phenoxy]pentanoic acid
• CAS: 147866-92-0
• 化学式: C₂₀H₂₂N₂O₅
• 分子量: 370.405
• InChiKey: NINWNYQHCGPTAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-[4-(Benzyloxycarbonylamino-imino-methyl)-phenoxy]-pentanoic acid 在 palladium on activated charcoal 盐酸 、 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 (S)-2-{(S)-2-[5-(4-Carbamimidoyl-phenoxy)-pentanoylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid
  参考文献：
  名称：

  Design, synthesis, and evaluation of fibrinogen inhibitors, ω-(p-amidinophenoxy) alkanoylaspartic acid derivatives

  摘要：

  Low molecular weight inhibitors of platelet aggregation are described. Compounds studied in this work were derived from the presumed active conformation of the adhesion tripeptide, ArgGlyAsp, using computer simulations. These studies led to the synthesis of a potent anti-platelet agent, 4-(4-amidinophenoxy)-butanoylaspartylvaline (6, FK633). Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0960-894x(96)00246-6
• 作为产物：
  描述：

  5-(4-氰基苯氧基)戊酸乙酯 在 盐酸 、 sodium hydroxide 、 氨 作用下， 以 乙醇 、 水 为溶剂， 反应 5.0h， 生成 5-[4-(Benzyloxycarbonylamino-imino-methyl)-phenoxy]-pentanoic acid
  参考文献：
  名称：

  Design, synthesis, and evaluation of fibrinogen inhibitors, ω-(p-amidinophenoxy) alkanoylaspartic acid derivatives

  摘要：

  Low molecular weight inhibitors of platelet aggregation are described. Compounds studied in this work were derived from the presumed active conformation of the adhesion tripeptide, ArgGlyAsp, using computer simulations. These studies led to the synthesis of a potent anti-platelet agent, 4-(4-amidinophenoxy)-butanoylaspartylvaline (6, FK633). Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0960-894x(96)00246-6

文献信息

• Peptide compound and a process for the preparation thereof
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05574016A1

  公开（公告）日：1996-11-12

  The present invention concerns glycoprotein IIa/IIIb antagonists and platelet aggregation inhibitors of the formula (I): ##STR1## wherein R.sup.1 is aryl which may have one or more suitable substituent(s), R.sup.2 is carboxy(lower)alkyl or protected carboxy(lower)alkyl, R.sup.3 is carboxy or protected carboxy, A.sup.1 is alkylene which may have one or more suitable substituent(s), A.sup.2 is a group of the formula: ##STR2## (wherein R is lower alkyl), or a group of the formula: --NHCH.sub.2 CH.sub.2 CO--, A.sup.3 is lower alkylene which may have one or more suitable substituent(s), l, m and n are each the same or different an integer of 0 or 1, with proviso that A.sup.2 is not a group of the formula: --NHCH.sub.2 CH.sub.2 CO--, when l is an integer of 0.

  本发明涉及式(I)的糖蛋白IIa/IIIb拮抗剂和血小板聚集抑制剂：其中R1是芳基，可以有一个或多个合适的取代基，R2是羧基（较低）烷基或保护羧基（较低）烷基，R3是羧基或保护羧基，A1是可以有一个或多个合适的取代基的烷基，A2是下列公式的基团：其中R是较低的烷基，或下列公式的基团：--NHCH2CH2CO--，A3是可以有一个或多个合适的取代基的较低烷基，l、m和n分别为0或1的整数，但当l为0的整数时，A2不是下列公式的基团：--NHCH2CH2CO--。
• New peptide compound and a process for the preparation thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0513675A1

  公开（公告）日：1992-11-19

  A peptide compound of the formula : wherein R¹ isaryl which may have one or more suitable substituent(s), R² iscarboxy(lower)alkyl or protected carboxy(lower)alkyl, R³ iscarboxy or protected carboxy, A¹ isalkylene which may have one or more suitable substituent(s), A² isa group of the formula : (wherein R⁴ is lower alkyl), or a group of the formula :         -NHCH₂CH₂CO- , A³ islower alkylene which may have one or more suitable substituent(s), ℓ, m and n areeach the same or different an integer of 0 or 1, with proviso that A² is not a group of the formula :         -NHCH₂CH₂CO- , when ℓ is an integer of 0, or a pharmaceutically acceptable salt thereof, processes for their preparation and pharmaceutical compositions comprising them.

  式中的多肽化合物 其中 R¹ 是芳基，可带有一个或多个合适的取代基、 R² 是羧基（低级）烷基或受保护的羧基（低级）烷基、 R³ 是羧基或受保护的羧基、 A¹ 是亚烷基，可带有一个或多个合适的取代基、 A² 是式中的基团： (其中 R⁴ 是低级烷基）、 或式 -NHCH₂CH₂CO-、 A³ 是低级亚烷基，可具有一个或多个合适的取代基、 ℓ、m 和 n 各为相同或不同的 0 或 1 的整数、 但 A² 不是式中的基团： -NHCH₂CH₂CO-、 当 ℓ 为 0、 或其药学上可接受的盐、它们的制备方法以及包含它们的药物组合物。
• US5574016A
  申请人：——

  公开号：US5574016A

  公开（公告）日：1996-11-12
• Design, synthesis, and evaluation of fibrinogen inhibitors, ω-(p-amidinophenoxy) alkanoylaspartic acid derivatives
  作者：Akito Tanaka、Hiroyoshi Sakai、Takatoshi Ishikawa、Isao Nakanishi、Mitsuru Ohkubo、Toshiaki Aoki、Yukio Motoyama、Hisashi Takasugi

  DOI：10.1016/s0960-894x(96)00246-6

  日期：1996.7

  Low molecular weight inhibitors of platelet aggregation are described. Compounds studied in this work were derived from the presumed active conformation of the adhesion tripeptide, ArgGlyAsp, using computer simulations. These studies led to the synthesis of a potent anti-platelet agent, 4-(4-amidinophenoxy)-butanoylaspartylvaline (6, FK633). Copyright (C) 1996 Elsevier Science Ltd